Strata Critical Medical reported a gross margin of 20.98% and a net margin of -14.50% for the quarter ended Jun 2026. These financial ratios cover 27 quarters of results from Dec 2019 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Ratios | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | |||||||||||||||||||||||||||
| Gross Margin | 20.95% | 10.98% | 12.90% | 15.82% | 17.00% | 21.81% | 18.98% | 19.68% | 24.07% | 20.82% | 13.78% | 19.62% | 19.97% | 23.56% | 17.47% | 20.95% | 20.98% | ||||||||||
| EBT Margin | -97.17% | -41.35% | 13.51% | -22.95% | -20.67% | 0.59% | -73.64% | -8.38% | -16.59% | -15.60% | -20.42% | -4.48% | -7.56% | -19.59% | -8.07% | 3.56% | -14.50% | ||||||||||
| EBIT Margin | -51.07% | -51.41% | -37.62% | -28.33% | -20.02% | -10.43% | -75.05% | -19.16% | -17.88% | -19.67% | -16.23% | -15.81% | -10.29% | -11.40% | -9.59% | -4.41% | -7.46% | ||||||||||
| EBITDA Margin | -51.07% | -51.41% | -37.62% | -28.33% | -20.02% | -10.43% | -75.05% | -19.16% | -17.88% | -19.67% | -16.23% | -15.81% | -10.29% | -11.40% | -9.59% | -4.41% | -7.46% | ||||||||||
| Operating Margin | -51.07% | -51.41% | -37.62% | -28.33% | -20.02% | -10.43% | -75.05% | -19.16% | -17.88% | -19.67% | -16.23% | -15.81% | -10.29% | -11.40% | -9.59% | -4.41% | -7.46% | ||||||||||
| Net Margin | -88.60% | -41.35% | 13.51% | -22.51% | -20.06% | 0.40% | -71.49% | -8.22% | -16.67% | -5.42% | -26.91% | -9.72% | -8.30% | 116.47% | -13.23% | 3.20% | -14.50% | ||||||||||
| FCF Margin | -37.32% | -40.23% | -36.66% | -38.66% | -14.66% | 1.86% | -19.68% | -31.77% | -11.38% | -3.37% | -17.39% | -7.96% | -11.75% | -81.53% | -15.21% | -1.92% | 4.41% | ||||||||||
| Efficiency | |||||||||||||||||||||||||||
| Assets AverageAssets Avg. | 344.77M | 339.64M | 331.26M | 325.41M | 325.42M | 325.84M | 323.73M | 321.31M | 318.85M | 306.23M | 288.87M | 281.56M | 281.64M | 269.81M | 253.61M | 254.23M | 296.50M | 330.27M | 326.55M | 330.16M | |||||||
| Asset Utilization RatioAsset Util. | 0.25 | 0.33 | 0.50 | 0.55 | 0.61 | 0.75 | 0.74 | 0.80 | 0.85 | 0.72 | 0.71 | 0.70 | 0.60 | 0.56 | 0.60 | 0.70 | 0.78 | ||||||||||
| Valuation | |||||||||||||||||||||||||||
| Price to EarningsP/E | -19.47 | -54.64 | 37.87 | -24.27 | -23.87 | 668.86 | -7.85 | -52.06 | -23.95 | -117.83 | -34.59 | -63.32 | -87.96 | 7.61 | -47.37 | 167.91 | -44.33 | ||||||||||
| Price to SalesP/S | 17.25 | 22.60 | 5.12 | 5.46 | 4.79 | 2.71 | 5.61 | 4.28 | 3.99 | 6.38 | 9.31 | 6.15 | 7.30 | 8.86 | 6.26 | 5.37 | 6.43 | ||||||||||
| Price to BookP/B | 2.52 | 2.14 | 2.14 | 1.09 | 1.02 | 0.94 | 0.92 | 1.12 | 0.74 | 1.14 | 0.93 | 1.18 | 0.99 | 1.53 | 1.01 | 1.48 | 1.54 | 1.50 | 1.27 | 1.67 | |||||||
| Enterprise Value | 429.62M | 342.02M | 332.67M | 62.42M | 86.54M | 65.81M | 70.36M | 122.32M | 20.07M | 100.14M | 69.46M | 129.26M | 93.91M | 211.56M | 101.17M | 215.81M | 361.10M | 357.19M | 302.89M | 443.47M | |||||||
| EV to EBIT | -19.78 | -24.30 | -2.67 | -5.49 | -10.02 | -2.70 | -2.81 | -7.04 | -10.64 | -13.24 | -35.83 | -17.80 | -46.50 | -64.23 | -55.77 | -101.85 | -82.00 | ||||||||||
| EV to EBITDA | -19.78 | -24.30 | -2.67 | -5.49 | -10.02 | -2.70 | -2.81 | -7.04 | -10.64 | -13.24 | -35.83 | -17.80 | -46.50 | -64.23 | -55.77 | -101.85 | -82.00 | ||||||||||
| Market Capitalization | 733.75M | 623.99M | 601.72M | 318.59M | 288.76M | 257.89M | 247.31M | 292.01M | 193.30M | 266.28M | 220.44M | 271.21M | 230.24M | 338.70M | 221.18M | 329.23M | 437.01M | 418.42M | 361.68M | 466.22M | |||||||
| Price to FCFP/FCF | -46.21 | -56.17 | -13.96 | -14.13 | -32.66 | 145.56 | -28.50 | -13.47 | -35.07 | -189.34 | -53.52 | -77.33 | -62.13 | -10.87 | -41.20 | -279.51 | 145.83 | ||||||||||
| EV to FCF | -27.06 | -31.05 | -2.73 | -4.02 | -13.68 | 15.11 | -10.72 | -4.24 | -16.71 | -77.22 | -33.43 | -35.37 | -40.73 | -8.98 | -35.17 | -234.07 | 138.71 | ||||||||||
| EV to CFO | -27.52 | -33.05 | -2.88 | -4.17 | -14.92 | 9.92 | -10.74 | -4.47 | 15.34 | 14.78 | -120.76 | -411.27 | -70.44 | -9.68 | -43.00 | 77.96 | 77.98 | ||||||||||
| Return Ratios | |||||||||||||||||||||||||||
| Return on Sales [ROS]ROS | -0.01% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -0.01% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.01% | 0.00% | 0.00% | 0.00% | ||||||||||
| Return on Capital Employed [ROCE]ROCE | -12.15% | -17.12% | -23.85% | -23.85% | -21.28% | -19.38% | -25.16% | -24.53% | -25.91% | -25.44% | -14.17% | -13.30% | -10.23% | -8.13% | -7.20% | -6.43% | -7.18% | ||||||||||
| Return on Assets [ROA]ROA | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |